Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer

References

• GroomePABolejackVCrowleyJJThe IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumoursJ Thorac Oncol20072869470517762335
   PubMed Web of Science ®Google Scholar
• PfisterDGJohnsonDHAzzoliCGAmerican Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003J Clin Oncol200422233035314691125
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in OncologyNon-small cell lung cancer v.2 Available from: http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdfAccessed May 18, 2011
   Google Scholar
• D’AddarioGFelipENon-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-upAnn Oncol200819Suppl 2ii39ii4018456762
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical ExcellenceClinical Guideline 24. Lung cancerThe diagnosis and treatment of lung cancer Available from: http://www.nice.org.uk/nicemedia/pdf/CG024niceguideline.pdfAccessed May 18, 2011
   Google Scholar
• BrodowiczTKrzakowskiMZwitterMCisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trialLung Cancer200652215516316569462
   PubMed Web of Science ®Google Scholar
• FidiasPMDakhilSRLyssAPPhase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancerJ Clin Oncol200927459159819075278
   PubMed Web of Science ®Google Scholar
• CappuzzoFCiuleanuTStelmakhLErlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studyLancet Oncol201011652152920493771
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyAvastin summary of product characteristics Available from: http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdfAccessed December 15, 2010
   Google Scholar
• European Medicines AgencyCommittee for Medicinal Products for Human Use post-authorisation summary of positive opinion for Tarceva Available from: http://www.emea.europa.eu/pdfs/human/opinion/51116606en.pdfAccessed May 18, 2011
   Google Scholar
• European Medicines AgencyCommittee for Medicinal Products for Human Use post-authorisation summary of positive opinion for Alimta Available from: http://www.emea.europa.eu/pdfs/human/opinion/Alimta_9292908en.pdfAccessed May 18, 2011
   Google Scholar
• European Medicines Agency Committee for medicinal products for human use (CHMP)Summary of opinion (post authorisation)Tarceva (erlotinib) Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000618/WC500075850.pdfAccessed May 18, 2011
   Google Scholar
• WeissteinEWGamma functionFrom ‘MathWorld’ – A Wolfram Web Resource Available from: http://mathworld.wolfram.com/GammaFunction.htmlAccessed May 18, 2011
   Google Scholar
• CollettDModelling Survival Data in Medical Research2nd edBoca Raton, FLChapman & Hall2003
   Google Scholar
• Official Gazette GHS 9606. [Chemotherapy for tumors, in session] Available from: http://www.legifrance.gouv.fr/affichTexte.do;jsessionid=244B4669551731582BF775EC93B44BD2.tpdjo09v_2?cidTexte=JORFTEXT000021879531&dateTexte=&oldAction=rechJO&categorieLien=idAccessed January 20, 2011 French
   Google Scholar
• GatzemeierUPirkOGabrielAKotowaWHeigenerDSecond-line-therapy for non-small cell lung cancer (NSCLC) – a retrospective cost analysisTumordiagn u Ther200829211217 German
   Google Scholar
• Conference of the Regions of Autonomous Provinces. Conventional single tariff for the provision of hospital care rules and rates applicable to the year 2009 Available from: http://www.regioni.it/upload/270110TUC_ASSISTENZA_OSPEDALIERA.pdfAccessed May 18, 2011 Italian
   Google Scholar
• BriggsASchulpherMClaxtonKDecision Modelling for Health Economic Evaluation1st edOxford, UKOxford University Press2006
   Google Scholar
• BischoffHGHeigenerDBanzKWalzerSCosts of treating severe adverse events observed with a regimen of bevacizumab plus chemotherapy versus cetuximab plus cisplatin/vinorelbine in the first-line therapy of advanced non-small cell lung cancer (NSCLC) in Germany [abstract]Value Health2009127A265 Abstr PCN47
   Web of Science ®Google Scholar
• ChouaidCVergnenegreABrunnerMWalzerSThe cost of treating grade 3/4 adverse events related to first-line therapy with bevacizumab plus chemotherapy versus cetuximab plus cisplatin/vinorelbine for patients with advanced non-small cell lung cancer (NSCLC) in France [abstract]Value Health2009127A264 Abstr PCN43
   Web of Science ®Google Scholar
• HeigenerDBischoffHGBanzKWalzerSCost savings related to superior adverse event profile of bevacizumab plus chemotherapy versus cetuximab plus cisplatin/vinorelbine in the first-line therapy of advanced non-small cell lung cancer (NSCLC) in Germany: a sensitivity analysis on the EGOG status [abstract]Value Health2009127A265 Abstr PCN46
   Web of Science ®Google Scholar
• KleinRWielageRMuehlenbeinCCost-effectiveness of pemetrexed as first-line maintenance therapy for advanced non-squamous non-small cell lung cancerJ Thorac Oncol2010581263127220581708
   PubMed Web of Science ®Google Scholar
• CascianoRBischoffHNuijtenMMalangoneERayJMaintenance erlotinib versus pemetrexed for the treatment of non-small cell lung cancer: indirect comparison applying real-life outcomes [abstract]Value Health2010137A254 Abstr PCN20
   Web of Science ®Google Scholar
• RaveraSWalzerSRayJCost comparison of erlotinib versus pemetrexed for the first-line maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer in Italy [abstract]Value Health2010137A259 Abstr PCN43
   Web of Science ®Google Scholar
• Castro de CarpenoJCastro-GómezAJWalzerSRayJCost comparison of erlotinib versus pemetrexed for the first-line maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer in Spain [abstract]Value Health2010137A259 Abstr PCN44
   Web of Science ®Google Scholar
• LearnPABachPBPem and the cost of multicycle maintenanceJ Thorac Oncol2010581111111220661082
   PubMed Web of Science ®Google Scholar
• CiuleanuTBrodowiczTZielinskiCMaintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 studyLancet200937496991432144019767093
   PubMed Web of Science ®Google Scholar
• NuijtenMJde Castro CarpenoJChouaidCA cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancerLung Cancer2011In press
   Web of Science ®Google Scholar
• Department of Health and SportsOrder of 27/02/2010 fixing for 2010 the tariff rules referred to in I and IV of Article L. 162-22-10 of the Code of Social Security and IV and V of the amended article 33 of the finance act 2004 for social securityOfficial Gazette No 502010 French
   Google Scholar